Navigation Links
Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
Date:5/26/2011

BONITA SPRINGS, Fla., May 26, 2011 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with or without Faslodex® (fulvestrant) in estrogen receptor (ER)-positive breast cancer patients. Molecular profiling will be used to pre-screen patients for a biomarker called Aryl Hydrocarbon Receptor (AhR), which has shown to predict sensitivity to AFP-464.

It is estimated that approximately 70 percent of breast cancers are ER-positive (1).

"The promise of personalized medicine is being realized with this study of AFP-464," said Edmundo Muniz, M.D., Ph.D., president and chief executive officer of Tigris Pharmaceuticals. "Matching specific markers and gene variations to particular medicines is a more efficient way of developing new anti-cancer agents and more importantly, will enable doctors to make more informed prescribing decisions, reducing risks of side effects and increasing chances of treatment success."

The primary endpoint of the study is to determine the percentage of patients that achieve a Clinical Benefit Response.

The randomized, proof-of-concept trial is led by Joanne Blum, M.D., Ph.D., director of the Hereditary Cancer Risk Program at Baylor-Sammons Cancer Center in Dallas, Texas. The study is open for accrual with the US Oncology Research Network, the largest community-based cancer research network in the nation.

"We are fortunate there are approved therapies to treat metastatic breast cancer, but the majority of patients with this disease will become refractory during  treatment," said Dr. Blum. "This study is exciting in that it may have the potential to improve our ability to deliver targeted cancer therapy at the outset of treatment providing another option for these patients.  Additionally, this agent may help to overcome endocrine resistance, one of the major problems for patients
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
2. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
3. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
6. Tragara Pharmaceuticals Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
7. Aeolus Pharmaceuticals, Inc. to Present Live, Online at RetailInvestorConferences.com on June 2nd
8. Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes
9. Reportlinker Adds Global: Pharmaceuticals Industry Guide
10. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
11. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS ... New York results of AFF008, a Phase I ... is the first therapy against the protein alpha-synuclein, a promising ... Michael J. Fox Foundation for Parkinson,s Research (MJFF) supported the ... the press conference on the impact a disease-modifying therapy would ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... , July 31, 2014 Vermillion, Inc. (NASDAQ: ... women,s health, will hold a conference call on Thursday, August ... for the second quarter ended June 30, 2014. Financial results ... call. Vermillion,s Chairman, President and CEO James ... and answer period. Date: Thursday, August 14, 2014 ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. ... Court has made the determination that a purchaser of tangible ... taxpayer was unable to prove during an audit that ... the Court of Appeals decision on whether a purchaser bears ... for purchases from Michigan sellers. The Court states “in order ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... recently released their innovative compression elbow sleeve , ... other elbow pain, in two new bright colors for ... neon pink and blue. Made of innovative proprietary Zensah® ... moisture wicking and odor-preventing fabric. It features a no-slip ...
(Date:7/31/2014)... 2014 Parker Waichman, LLP, a national ... comments that whistleblowers are a critical component of the ... that may cause harm to consumers and may defraud ... Appreciation Day. , According to a 2013 report issued ... declared "National Whistleblower Appreciation Day" on July 30, 2013; ...
(Date:7/31/2014)... 31, 2014 CarePoint Health is ... Masood Rizvi, has joined our network, CarePoint Health ... the community. Hundreds of highly skilled and experienced ... network of top doctors and practices in Hudson ... latest acquisition represents CarePoint Health’s commitment to provide ...
(Date:7/31/2014)... CT (PRWEB) July 31, 2014 You’re having ... So why have you suddenly developed chills and fever, headache, ... If you suspect a flu-like illness, it could actually be ... , Your risk of developing Lyme is greater than you ... 30,000 new cases occurred in the U.S. annually. But the ...
Breaking Medicine News(10 mins):Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 2Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 4Health News:Dr. Rizvi Joins CarePoint Health Medical Group 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3
... equal for both procedures , , FRIDAY, May 16 ... for colon cancer produce similar outcomes, according to researchers ... 3,300 patients. , "For a long time, many ... in colorectal cancer patients and cause metastases in the ...
... ,Click It or Ticket ... Local high schoolers display art and videos promoting seat belt use, CLEVELAND, May ... mobilization, When: Monday, May 19, 2008 ... 11:30 AM), Where: The Cleveland House of Blues ...
... of CSL Behring, maker of Zemaira(R), Alpha-1 Proteinase Inhibitor (Human) ... ... PRUSSIA, Pa., May 17 Melissa Biggs, a fashion,designer and actress who ... of CSL Behring, and is,urging Americans to get tested for alpha-1 antitrypsin ...
... & Back; Merger Sets Up Healthy ... Back Retail Chain, LORTON, Va., May 16 ... and workplace back wellness created an,ergonomic revolution, has acquired ... Healthy Back,s 18 stores and ecommerce division,claimed 2007 revenues ...
... There,s more to a healthy mouth than,flashing a ... America,s oral care,habits - and what it means ... report from Oral Health America & Philips Sonicare ... video, audio, text, graphics and,photos for free and ...
... report side effects, but critics want agency to act, ... -- Direct-to-consumer drug ads on television should include a ... adverse side effects, U.S. health experts suggested Friday. , ... U.S. Food and Drug Administration. Such phone numbers are ...
Cached Medicine News:Health News:Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:The Back Wars Come to a Close 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
Gills Colibri forceps, very fine pointed tips....
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Girard angled tying forceps made of titanium has angled 45 shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 102 mm....
McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....
Medicine Products: